SOLIRIS is the first and only FDA-approved treatment for PNH

PNH is a rare blood disorder in which red blood cells are chronically destroyed by a process called "hemolysis." The ongoing destruction of red blood cells leads to the signs and symptoms of PNH such as anemia, often requiring transfusions, disabling fatigue, recurrent pain, impaired quality of life, shortness of breath, and blood clots.

SOLIRIS® (eculizumab) works by targeting and reducing hemolysis — the underlying cause of PNH symptoms. By reducing red blood cell destruction, or hemolysis, treatment with SOLIRIS improves anemia, fatigue and other symptoms and helps PNH patients enjoy a better quality of life. In clinical trials, patients experienced fewer blood clots with SOLIRIS treatment as compared to the same period of time prior to treatment.

Talk to your doctor to see if SOLIRIS is right for you.

Do You or a Loved One Have PNH?

Do you or a loved one have PNH?
   

Learn about SOLIRIS

Learn about SOLIRIS
   

Sign Up!

Sign Up Now!
Learn about the SOLIRIS access and reimbursement support program

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.